School of Hainan Provincial Drug Safety Evaluation Research Center, Hainan Medical University, Haikou, China.
Department of Key Specialist Office, Sanya Hospital of Traditional Chinese Medicine, Sanya, China.
J Cell Mol Med. 2024 Nov;28(21):e70185. doi: 10.1111/jcmm.70185.
5-fluorouracil (5-FU) is a preferred chemotherapeutic agent for the treatment of colon cancer. Nonetheless, its clinical effectiveness is frequently hampered by suboptimal therapeutic outcomes and the emergence of drug resistance. Therefore, there exists a pressing demand for novel therapeutic agents to circumvent chemoresistance. The pregnane X receptor (PXR) exerts a pivotal regulatory influence on the proliferation, invasion, and chemoresistance mechanisms in colon cancer. Activation of PXR drives up the transcription of the multidrug resistance gene (MDR1), thus prompting the expression of P-glycoprotein (P-gp) responsible for conferring tumour resistance. This study scrutinized the potential of Fengliao Changweikang (FLCWK) in augmenting the efficacy of 5-FU in the management of colon cancer. To this end, we engineered colon cancer cells with varied levels of PXR expression via lentiviral transfection, subsequently validating the findings in nude mice. By means of MTT assays, flow cytometry apoptosis analysis, Western blotting and immunofluorescence, we probed into the prospective impacts of FLCWK and 5-FU on cellular viability and resistance. Our results revealed that while upregulation of PXR amplified the therapeutic benefits in colon cancer treatment, it concurrently heightened resistance levels. FLCWK demonstrated a capacity to reduce P-gp expression, with the combined administration of FLCWK and 5-FU effectively reversing resistance mechanisms. Furthermore, activation of PXR was found to impede the IL-6/STAT3 signalling pathway. In an effort to mimic the development of colon cancer, we established an azomethane oxide (AOM)/ dextran sodium sulfate (DSS) mouse model, showing that FLCWK bolstered the inhibitory effects of 5-FU, impeding the progression of colon cancer. In summation, our findings point towards the potential of FLCWK in the treatment of colon cancer, particularly in strengthening the therapeutic efficacy of 5-FU in the prevention and control of the disease.
氟尿嘧啶(5-FU)是治疗结肠癌的首选化疗药物。然而,其临床疗效常常受到治疗效果不佳和耐药性出现的阻碍。因此,迫切需要新的治疗药物来规避化疗耐药性。孕烷 X 受体(PXR)对结肠癌的增殖、侵袭和耐药机制发挥着关键的调节作用。PXR 的激活会导致多药耐药基因(MDR1)的转录增加,从而促使负责赋予肿瘤耐药性的 P-糖蛋白(P-gp)表达。本研究探讨了丰乐肠康宁(FLCWK)在增强 5-FU 治疗结肠癌疗效方面的潜力。为此,我们通过慢病毒转染工程化具有不同 PXR 表达水平的结肠癌细胞,并在裸鼠中验证了这些发现。通过 MTT 检测、流式细胞术凋亡分析、Western blot 和免疫荧光,我们研究了 FLCWK 和 5-FU 对细胞活力和耐药性的潜在影响。我们的结果表明,虽然 PXR 的上调增强了结肠癌治疗的疗效,但同时也提高了耐药水平。FLCWK 显示出降低 P-gp 表达的能力,联合使用 FLCWK 和 5-FU 可有效逆转耐药机制。此外,我们发现 PXR 的激活会抑制 IL-6/STAT3 信号通路。为了模拟结肠癌的发展,我们建立了偶氮甲烷氧化物(AOM)/葡聚糖硫酸钠(DSS)小鼠模型,结果表明 FLCWK 增强了 5-FU 的抑制作用,阻止了结肠癌的进展。总之,我们的研究结果表明 FLCWK 具有治疗结肠癌的潜力,特别是在增强 5-FU 在预防和控制疾病方面的治疗效果。